

June 16, 2015

## INDIAN PHARMACEUTICAL INDUSTRY AND ITS GROWTH

22

15 180 1 27.5% 2 2014 40%

5 2016 270 3  
 API 4  
 78 4

FDI  
FDI  
FIPB

100% FDI  
 100% FDI  
 100% FDI

FIPB

- a) 1940 1945
- b) 1954 1955
- c) 1970 20
- d) 2013 DPCO; 2011
- e) UCPMP
- f) 1961 40% 18.5%

## Taxing Offshore Indirect Transfers in India

February 28, 2025

## Unlocking Corporate Philanthropy

February 27, 2025

## Digital Health in India

February 26, 2025

## Re-Evaluating Press Note 3 Of 2020: Should India's Land Borders Still Define Foreign Investment Boundaries?

February 04, 2025

## INDIA 2025: The Emerging Powerhouse for Private Equity and M&A Deals

January 15, 2025

## Key changes to Model Concession Agreements in the Road Sector

January 03, 2025

### CCI's Deal Value Test

February 22, 2025

## Securities Market Regulator's Continued Quest Against "Unfiltered" Financial Advice

December 18, 2024

## Digital Lending - Part 1 - What's New with NBFC P2Ps

November 19, 2024

Connect with us at events,  
conferences and seminars.

[Click here to view Hotline archives.](#)

Arbitration Amendment Bill 2024: A Few Suggestions | Legally Speaking With Tarun Nangia | NewsX

February 12, 2025

g) 1963

h)  VAT

i) 1994 Excise Duty CENVAT

j) 1994

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

Japan.nda(at)nishithdesai.com

**1** □□□□□□FDI□□□□□□□□□□□□□□  
□□[http://dipp.nic.in/English/Publications/FDI\\_Statistics/2015/india\\_FDI\\_February2015.pdf](http://dipp.nic.in/English/Publications/FDI_Statistics/2015/india_FDI_February2015.pdf) □2015□6□2□□□□□□

**2** □□□FDI□□□□□□□□□□□□[http://dipp.nic.in/English/Investor/Japan\\_Desk/FDI\\_Synopsis\\_Japan.pdf](http://dipp.nic.in/English/Investor/Japan_Desk/FDI_Synopsis_Japan.pdf) □2015□6□2□□□□□□

**3** □□□□□□□□□□270□□□: □□□□□□ □□□□□□□□□□2014□2□16□□□□□□□□□□□□  
□[http://articles.economictimes.indiatimes.com/2014-02-16/news/47379629\\_1\\_chronic-therapies-health-awareness-life-sciences](http://articles.economictimes.indiatimes.com/2014-02-16/news/47379629_1_chronic-therapies-health-awareness-life-sciences) □2014□10□16□□□□□□

**4** □□□□□□□□□CRAMS□□□□CARE □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□  
□<https://researchreports.careratings.com/industries/crams-industry.html> □2014□10□16□□□□□□

## DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

## What India's Transition to New Data Protection Law Means for Global Businesses

## India 2025: The Emerging Powerhouse for Private Equity and M&A Deals

January 16, 2025